3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Neoplasms
19
Endometrial Neoplasms
14
Ovarian Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Neoplasm Metastasis
7
Squamous Cell Carcinoma of Head and Neck
6
Uterine Cervical Neoplasms
5
Head and Neck Neoplasms
5
Breast Neoplasms
5
Rectal Neoplasms
4
Pancreatic Neoplasms
4
Melanoma
4
Lung Neoplasms
4
Colonic Neoplasms
4
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Osteosarcoma
2
Multiple Myeloma
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Interventions
Doxorubicin
141
Ifosfamide
85
Radiotherapy
80
Cyclophosphamide
72
Gemcitabine
63
Filgrastim
54
pembrolizumab
43
pazopanib
39
Etoposide
39
Docetaxel
39
Vincristine
37
Cisplatin
35
Trabectedin
32
Nivolumab
32
Irinotecan
26
Magnetic Resonance Spectroscopy
25
Carboplatin
25
Temozolomide
23
Ipilimumab
22
Bevacizumab
20
Radiation
19
Granulocyte Colony-Stimulating Factor
18
Surgical Procedures, Operative
17
Sirolimus
17
Mesna
17
Melphalan
17
Dactinomycin
17
Biopsy
17
eribulin
16
Specimen Handling
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma
×
dostarlimab
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled